Pricing Log in Create free account

Emergent Biosolutions Inc. (EBS) vs Evotec AG (EVO)

Emergent Biosolutions Inc. and Evotec AG are both Drug Manufacturers Specialty & Generic companies. Evotec AG is the larger, with a market value of $504.4M against $368.1M — 1.4× the size. Evotec AG grew revenue faster over the last twelve months: 2.15% against −9.56%. Emergent Biosolutions Inc. has the higher net margin (−23.0% vs −26.2%) and the lower return on invested capital (−5.27% vs 0.00%). Across the 19 metrics below, Evotec AG leads on 11 and Emergent Biosolutions Inc. on 8.

Valuation

Metric EBS EVO Drug Manufacturers Specialty & Generic median
P/E n/m n/m 19.25
P/S 0.43 0.57 2.11
P/B 0.96 0.63 1.78
Price to free cash flow 3.82 n/m 16.14
EV/EBITDA 20.89 n/m 12.58
EV/Sales 1.00 0.58 2.73
Earnings yield (53.92%) (46.23%) (4.38%)
Free cash flow yield 26.15% (40.86%) 0.00%

Profitability

Metric EBS EVO Drug Manufacturers Specialty & Generic median
Gross margin 55.87% 11.42% 53.94%
Operating margin (8.57%) (21.35%) 0.00%
Net margin (22.96%) (26.20%) 0.00%
Free cash flow margin 11.18% 0.00% 0.00%
Return on equity (40.29%) 0.00% (0.40%)
Return on assets (13.95%) 0.00% (3.32%)
Return on invested capital (5.27%) 0.00% 0.00%

Growth

Metric EBS EVO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (9.56%) 2.15% 10.01%
EPS growth (last fiscal year) 125.83% 44.89% 49.06%
Revenue growth, 5-year CAGR (13.74%) 9.28% 6.74%
Net income growth, 5-year CAGR (29.64%) 0.00% 0.00%

Health

Metric EBS EVO Drug Manufacturers Specialty & Generic median
Debt to equity 1.70 0.72 0.05
Current ratio 5.42 2.33 2.31
Net debt to EBITDA 1.76 (0.64) 0.97

Dividend

Metric EBS EVO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric EBS EVO Drug Manufacturers Specialty & Generic median
Market cap 368.14m 504.36m 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack